PET imaging of arthritis by specific macrophage targeting in Rheumatoid Arthritis patients - clinical proof of concept studies - Macrophage PET imaging of arthritis in Rheumatoid Arthritis patients

Vrije Universiteit Medisch Centrum0 个研究点目标入组 18 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1. Men or women, * 18 years old
•2. Diagnosis of rheumatoid arthritis according to the 1987 revised criteria of the American Rheumatism Association (ARA) and/or the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria.
•3. Patients with obvious clinical arthritis activity assessed by a physician, in at least 2 hand, wrist or knee joints.
•4. Treatment with disease modifying anti-rheumatic drugs (DMARDS) and oral corticosteroids up to 10 mg daily is allowed. Non-steroidal anti-inflammatory drugs (NSAID) is permitted, provided that there is a stable dose for at least 1 month. Furthermore, prior or current treatment with biologics is permitted, provided that there is a stable dosing schedule for at least 3 months.
•5. Patients must be able to adhere to the study appointments and other protocol
•requirements.
•6. Patients must be capable of giving informed consent and the consent must have been
•obtained prior to the study related procedures.

•1. Use of intramuscular or intravenous corticosteroids within 4 weeks prior to screening.
•2. Treatment with any investigational drug within the previous 3 months.
•3. Pregnancy or breast-feeding.
•4. Previous exposure to radioactivity with a yearly cumulative dose of * 5 mSv.

发起方